enGene Holdings Inc. (NASDAQ:ENGN) Receives $34.40 Average Price Target from Brokerages

Shares of enGene Holdings Inc. (NASDAQ:ENGN) have earned a consensus recommendation of “Buy” from the six analysts that are presently covering the stock, MarketBeat reports. Six research analysts have rated the stock with a buy rating. The average 1-year price objective among brokerages that have covered the stock in the last year is $34.40.

A number of equities analysts have issued reports on the stock. Wells Fargo & Company assumed coverage on shares of enGene in a report on Monday. They set an “overweight” rating and a $30.00 price objective on the stock. Leerink Partnrs reaffirmed an “outperform” rating on shares of enGene in a report on Tuesday, February 20th. SVB Leerink assumed coverage on shares of enGene in a report on Tuesday, February 20th. They set an “outperform” rating and a $31.00 price objective on the stock. Guggenheim initiated coverage on shares of enGene in a report on Monday, April 15th. They set a “buy” rating and a $34.00 price objective on the stock. Finally, UBS Group initiated coverage on enGene in a research note on Thursday, March 28th. They set a “buy” rating and a $37.00 target price on the stock.

enGene Price Performance

NASDAQ ENGN opened at $14.75 on Monday. The company has a fifty day simple moving average of $16.23. enGene has a 12-month low of $6.69 and a 12-month high of $43.00.

Insider Activity at enGene

In other news, major shareholder De Solidarite Des Travai Fonds sold 4,575 shares of the company’s stock in a transaction dated Thursday, April 18th. The stock was sold at an average price of $15.01, for a total transaction of $68,670.75. Following the sale, the insider now directly owns 3,084,107 shares in the company, valued at $46,292,446.07. The sale was disclosed in a document filed with the SEC, which is available at this link.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Fcpm Iii Services B.V. purchased a new stake in enGene in the fourth quarter worth approximately $80,097,000. BVF Inc. IL purchased a new stake in enGene in the fourth quarter worth approximately $20,777,000. Omega Fund Management LLC purchased a new stake in enGene in the fourth quarter worth approximately $10,441,000. Finally, Vivo Capital LLC purchased a new stake in enGene in the fourth quarter worth approximately $6,264,000. Hedge funds and other institutional investors own 64.16% of the company’s stock.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.